Compare Organon Pharma Indonesia Tbk. (SCPI) vs Super Bank Indonesia Tbk. (SUPA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Super Bank Indonesia Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Super Bank Indonesia Tbk. trades at Rp505 (market cap 17.11T, 11.9M 24h volume). The key difference: Super Bank Indonesia Tbk. is far larger — about 163.9× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SUPA | |
|---|---|---|
Market Cap | 104.4B | 17.11T |
Volume | — | 11.9M |
Lot | — | 119.04K |
Turnover | — | 6B |
Average Price | — | 504.24 |
Value | — | 6B |
Indicative Equilibrium Price | — | 505 |
Indicative Equilibrium Volume | — | 1.29K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Super Bank Indonesia Tbk.
PT Super Bank Indonesia Tbk. (hereinafter referred to as the Bank) formerly under the name of PT Bank Fama International was established by Deed No. 36 on 5 March 1993, before Notary Herlien, S.H. The Bank has received a license as a commercial bank according to the Decree of the Minister of Finance of the Republic of Indonesia No. 834/KMK.017/1993 dated 11 October 1993.
Read more on SUPA →
